Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00381654 · ClinicalTrials.gov registry record · Phase 1
Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies
A Phase 1 study, sponsored by AVEO Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00381654 is a Phase 1 study that was terminated before completion, run by AVEO Pharmaceuticals. The registered enrollment target is 27 participants.
The verdict
NCT00381654, a Phase 1 study, was terminated before completion, sponsored by AVEO Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
AV-412 is a new oral therapy developed to inhibit the growth of solid tumors in patients who have not responded to standard therapy or surgical interventions, or who have experienced relapse. This study will test the safety of AV-412 and determine the maximum tolerated dose for the treatment of solid tumors.
Interventions
- DRUG AV-412
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2006-10 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00381654
The ClinicalTrials.gov registry entry for NCT00381654 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AVEO Pharmaceuticals, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AV-412 is the first listed.
NCT00381654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00381654 about?
NCT00381654 is a clinical study titled "Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies". AV-412 is a new oral therapy developed to inhibit the growth of solid tumors in patients who have not responded to standard therapy or surgical interventions, or who have experienced relapse. This study will test the safety of AV-412 and determine the maximum tolerated dose for the treatment of soli...
What is the current status of trial NCT00381654?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2006-10. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00381654?
The interventions under investigation include: AV-412 (DRUG).
Who is sponsoring clinical trial NCT00381654?
This trial is sponsored by AVEO Pharmaceuticals, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.